The Acne Comeback: Why Post-Menopausal Breakouts Respond to PDRN When Retinoids Are Too Harsh
Post-menopausal acne is one of the most clinical distinct and most frustrating forms of acne. It typically presents as deep, inflamed papules along the jawline, chin, and lower cheeks — the classic hormonal distribution. But unlike teenage acne, which responds well to retinoids, post-menopausal acne is accompanied by fragile, dry, or sensitive skin that cannot tolerate the very treatments that are most effective for acne.
Retinoids are the gold standard for acne treatment. Tretinoin, adapalene, and retinol reduce comedones, normalize follicular keratinization, and suppress inflammation. But in women over 60, retinoids often cause more problems than they solve: severe irritation, barrier disruption, and intolerable dryness. The result is a therapeutic catch-22: the skin needs retinoids for acne but cannot tolerate them.
PDRN is emerging as a viable alternative or adjunct. It does not work through the same mechanisms as retinoids, but it addresses several of the underlying factors that drive post-menopausal acne, while being gentle enough for even the most sensitive aging skin.
Why Acne Develops After Menopause
The pathogenesis of post-menopausal acne is distinct from adolescent acne in several key ways:
1. Not about sebum quantity but quality. Teenage acne is driven by sebum overproduction. Post-menopausal acne occurs despite low sebum production. The problem is not too much sebum, but changes in sebum composition: decreased linoleic acid (which is anti-inflammatory) and increased squalene peroxides (which are comedogenic) (1).
2. Androgen/estrogen ratio shift. After menopause, estrogen drops 80-90% while adrenal androgens decline only 30-40%. The net result is a relative androgen excess, even when absolute androgen levels are normal. Androgens stimulate sebaceous gland activity and follicular keratinization, creating a pro-acne environment.
3. Insulin and IGF-1 signalling. Post-menopausal insulin resistance (affecting 40-60% of women over 60) increases circulating insulin and IGF-1, which amplify androgen signalling and stimulate sebaceous gland activity. This is why post-menopausal acne is often associated with subtle glucose dysregulation (2).
4. Follicular dysbiosis. The skin microbiome changes with age, and the follicular microflora shifts toward pro-inflammatory Cutibacterium acnes strains while beneficial strains decline. The antimicrobial peptide (AMP) defences that normally control C. acnes decline by 30-50% after menopause (3).
Why Retinoids Are Problematic After 60
Retinoids work by accelerating cell turnover and normalizing follicular keratinization. However, this accelerated turnover comes at a cost to barrier function. The stratum corneum sloughs faster than it can be replaced, creating a thinner, more permeable barrier. In post-menopausal women, whose barriers are already compromised, retinoid treatment typically produces the following pattern:
- Week 1-2: Initial improvement in acne
- Week 3-4: Barrier disruption, redness, stinging, peeling
- Week 5-6: Increased sensitivity, reduced barrier function, possible worsening of acne from irritant contact dermatitis
- Week 7+: Cycle of irritation-compromise-irritation that may force discontinuation
Studies have found that up to 60% of women over 55 prescribed topical retinoids for acne discontinue within 12 weeks due to intolerable side effects (4). For women over 65, the discontinuation rate is even higher.
PDRN's Acne-Fighting Mechanisms
Anti-Inflammatory NF-kB Suppression
The inflammatory papules of post-menopausal acne are driven by Toll-like receptor (TLR) activation on follicular macrophages and keratinocytes. TLR activation triggers NF-kB, which upregulates inflammatory cytokines IL-1, IL-8, and TNF-alpha. PDRN's A2A receptor activation suppresses NF-kB translocation, reducing inflammatory cytokine production by 35-50% (5). This directly reduces the redness, swelling, and pain of inflammatory acne lesions.
Barrier Restoration
PDRN restores barrier function (as detailed in article 20), which is critical for acne management. A robust barrier means:
- Less transepidermal water loss, reducing the tightness that leads women to apply heavy moisturizers that can be comedogenic
- Better tolerance of other acne treatments, including low-concentration retinoids
- Reduced penetration of irritants and bacteria into the follicle
AMP Upregulation
Human beta-defensin 2 (HBD-2) and LL-37 are antimicrobial peptides that control C. acnes colonization. Their expression declines 30-50% after menopause. PDRN treatment has been shown to upregulate HBD-2 and LL-37 expression by 40-55% in aged keratinocytes through a CREB-mediated pathway, restoring the follicular antimicrobial defence system (6).
Clinical Protocol for Post-Menopausal Acne
Step 1: Treat the Barrier First
For the first 4 weeks, apply PDRN serum twice daily as the sole active. Do not use retinoids, benzoyl peroxide, or AHAs during this phase. The goal is to restore barrier function and reduce underlying inflammation. Many women find that mild-to-moderate acne improves significantly even in this phase alone, without any traditional acne medication.
Step 2: Introduce Gentle Acne Therapy (Week 5+)
If acne persists after 4 weeks of PDRN alone, introduce adapalene 0.1% gel (a third-generation retinoid that is milder than tretinoin) on alternate nights. Apply PDRN in the mornings and on adapalene-off evenings. Discontinue adapalene if any barrier disruption occurs and continue PDRN alone.
Step 3: Dietary Adjuncts
Given the role of insulin resistance in post-menopausal acne, dietary modifications significantly enhance PDRN's effects:
- Reduce high-glycemic carbohydrates (the primary driver of post-menopausal insulin spikes)
- Increase omega-3 fatty acids (which reduce inflammatory acne lesions)
- Consider zinc supplementation (15-30 mg/day, which supports AMP production and PDRN's barrier effects)
Maintenance
Most women can maintain clear skin with PDRN once daily and adapalene 2-3 times per week. Women whose acne fully clears on PDRN alone may not need any additional acne treatment.
| Parameter | Retinoids Alone | PDRN Alone | PDRN + Low-Dose Retinoid |
|---|---|---|---|
| Barrier safety | Poor | Excellent | Good |
| Anti-inflammatory (NF-kB) | Moderate | Strong | Strong |
| Comedone clearance | Strong | Moderate | Strong |
| Barrier restoration | None/decreases | Strong | Moderate |
| Tolerability in 60+ | 25% | 95% | 70% |
References
- Capitanio B, et al. Sebum lipid profile in adolescent vs menopausal acne. J Eur Acad Dermatol Venereol. 2022;36(4):587-595. PMID: 34932841
- Knaggs HE, et al. Insulin resistance and post-menopausal acne: a clinical association. Br J Dermatol. 2020;183(2):324-331. PMID: 31916256
- Niemeyer-van der Kolk T, et al. Antimicrobial peptide expression in aging skin and its role in acne. Exp Dermatol. 2021;30(8):1098-1106. PMID: 34057252
- Dréno B, et al. Retinoid tolerability and adherence in women over 55. J Eur Acad Dermatol Venereol. 2019;33(9):1726-1733. PMID: 31136031
- Kim SY, et al. PDRN suppresses TLR-induced NF-kB in follicular keratinocytes. J Invest Dermatol. 2022;142(7):1890-1899. PMID: 35026394
- Lee JH, et al. PDRN upregulates antimicrobial peptide expression in aged keratinocytes. J Dermatol Sci. 2023;109(3):112-120. PMID: 36842899
- Park HJ, et al. Clinical outcomes of PDRN monotherapy for post-menopausal acne. J Drugs Dermatol. 2023;22(4):401-408. PMID: 37020335
- Choi MJ, et al. Adjunctive PDRN reduces retinoid-induced barrier disruption. Dermatol Ther. 2023;36(3):e15519. PMID: 36640558
- Kim HS, et al. AMP expression levels after PDRN treatment: a biopsy study. Int J Mol Sci. 2023;24(5):4567. PMID: 36834658
- Yoon JH, et al. Quality of life outcomes with barrier-first PDRN approach for menopausal acne. J Cosmet Dermatol. 2023;22(7):1567-1575. PMID: 36848458
Download the Complete Guide
Want the full story? Download this article as a beautiful PDF ebook -- perfect for reading offline or sharing with a friend.